Obesity drug
Study
Investigational monoamine reuptake inhibition; evidence-quality caveat applies.12
MetabolicSmall molecule
Tesofensine
Monoamine reuptake inhibitor
Not FDA approved; the key early efficacy paper has an expression of concern.
What does it do?
Molecular information
3Amino-acid sequence
Not applicable: this compound is not a single peptide.
LengthNot a peptide sequence
Molecular weight · DaNot independently verified for the exact supplied form
Molecular formulaNot independently verified for the exact supplied form3
Salt, hydration, glycosylation and blend composition may change the supplied material; no unsupported formula or mass is assigned.
Pharmacokinetics
Unverified reference estimateNot independently confirmed
Reference half-life9.2 days8
Route / formulationSource page: Oral. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 46 d
Five half-lives in this estimated model. This is not a prediction of when effects stop.
About this estimate
Population: Not established by the reference estimate
Source’s stated attribution: Phase 2/3 Clinical Trials
Source’s reported peak time: 8 hrs. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Major evidence-quality caveat
The Lancet issued an expression of concern about the widely cited 2008 trial. Its headline weight-loss estimates should not be presented as uncontested evidence.12
Reported timelines
Reference & communitySource expectations
Appetite 1–2 weeks; weight change 2–4 weeks through 3–6 months. Persistence for weeks is plausible, not proof of stable effects.9
These are reported timelines, not a prediction of your response.
Doses & schedules
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| Oral | 0.25 mg | Once daily | TIPO-1 phase II study203 adults with obesityHuman study | 24 weeks | 1 |
Population 203 adults with obesity Context The publication has an expression of concern; protocol description is not a recommendation. Source dose wording 0.25, 0.5 or 1.0 mg | |||||
| Oral | 0.5 mg | Once daily | TIPO-1 phase II study203 adults with obesityHuman study | 24 weeks | 1 |
Population 203 adults with obesity Context The publication has an expression of concern; protocol description is not a recommendation. Source dose wording 0.25, 0.5 or 1.0 mg | |||||
| Oral | 1 mg | Once daily | TIPO-1 phase II study203 adults with obesityHuman study | 24 weeks | 1 |
Population 203 adults with obesity Context The publication has an expression of concern; protocol description is not a recommendation. Source dose wording 0.25, 0.5 or 1.0 mg | |||||
| Oral | 0.5 mg | Once daily in the morning | Standard Weight LossReference report | 12-24 weeks typical in clinical trials | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Reference contraindication labels describe precautions for an investigational compound, not a U.S. prescribing label. Source tabs Oral | |||||
| Oral | 0.25 mgStarting dose | Once daily in the morning | Conservative/Starting DoseReference report | 12-24 weeks typical in clinical trials | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Reference contraindication labels describe precautions for an investigational compound, not a U.S. prescribing label. Source tabs Oral | |||||
| Oral | 1.0 mg | Once daily (higher side effect rate) | Maximum Studied DoseReference report | 12-24 weeks typical in clinical trials | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Reference contraindication labels describe precautions for an investigational compound, not a U.S. prescribing label. Source tabs Oral | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Oral
- Use period
- 12-24 weeks typical in clinical trials
- Break
- Unknown - long half-life means effects persist weeks after stopping
Reported timing
Morning dosing recommended due to stimulant-like effects
Side effects & safety
Heart-rate and tolerability signals
The paper reported increased heart rate and dry mouth, GI symptoms and insomnia; its expression of concern also limits confidence in safety estimates.
12Common
Dry mouth, insomnia, pulse and BP increases.
Serious
Serotonergic, seizure and cardiovascular risks; long persistence can prolong adverse effects.
Stop symptoms
Chest pain/dyspnea, palpitations, sustained BP rise, severe insomnia/headache, dehydration, agitation/fever/rigidity or suicidal mood changes.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
SSRIs
Avoidance reportedSerotonergic overlap.9
Reference report · Pep-Pedia label: Avoid CombinationSNRIs
Avoidance reportedSerotonin/noradrenaline overlap.9
Reference report · Pep-Pedia label: Avoid CombinationMAOIs
Avoidance reportedPotential hypertensive/serotonergic crisis.9
Reference report · Evidence context: ContraindicatedStimulants
Avoidance reportedCardiovascular stress.9
Reference report · Pep-Pedia label: Avoid CombinationBupropion
Avoidance reportedSeizure/BP concerns.9
Reference report · Pep-Pedia label: Avoid CombinationCaffeine
Caution reportedStimulation/BP concerns.9
Reference report · Pep-Pedia label: Use CautionSemaglutide / tirzepatide
Unverified pairingUntested pairing.9
Reference report · Evidence context: Insufficient dataBeta-blockers
Unverified pairingStudied pairing, not DIY protection.9
Reference report · Evidence context: Potentially beneficialOther medicines and research compounds
Not establishedNo clinical interaction study for the exact proposed combination was verified; absence of evidence does not establish compatibility.3
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No universal bacteriostatic-water volume or validated preparation method is established for this entry.3
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Oral
The source describes capsules or measured oral material rather than vial reconstitution.
- Form
- Source describes a prepared product
- Reported parameters
- Storage follows the oral product instructions.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported variationNot FDA ApprovedReported variationCompounded ProductsReported appearanceThird-Party TestingReported appearanceProper DosingReported concernUnknown SourcesReported concernCombination Products
9Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
No applicable mixing data
The available sources describe prepared products or do not establish a reconstitution method.9
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →Research-market product identity, purity and formulation cannot be established from a publication.12
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
Human trialsSource context
Reference contraindication labels describe precautions for an investigational compound, not a U.S. prescribing label.
Compound identity & other names
An oral drug investigated for obesity. The widely cited 2008 weight-loss trial has a published expression of concern, which materially limits confidence in that result.
Not FDA approved; the key early efficacy paper has an expression of concern.
Monoamine reuptake inhibitor3
How it may work
Raises dopamine, noradrenaline and serotonin signaling, influencing appetite and energy regulation.9
Major evidence-quality caveat
The Lancet issued an expression of concern about the widely cited 2008 trial. Its headline weight-loss estimates should not be presented as uncontested evidence.
12Research areas and evidence gaps
Obesity drug research. Investigational monoamine reuptake inhibition; evidence-quality caveat applies.12
- Research-market product identity, purity and formulation cannot be established from a publication.
Additional uses listed by Pep-Pedia
Weight. Appetite, total/visceral fat and weight-loss research.9
Metabolic. Energy expenditure, insulin sensitivity and lipids.9
Community reports Unvalidated
Weight discussions as described by Pep-Pedia.3
No representative survey, independently verified products, or controlled outcomes.
Search coverage and review status
The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.
- Checked
- 2026-10-12
- Search
- tesofensine 2025 2026 trial site:pubmed.ncbi.nlm.nih.gov
- Catalog
- Pep-Pedia ↗ · 5 listed references retained
- Targeted search, not an exhaustive systematic review.
- Bibliography-only entries are retained for traceability and are not treated as verified findings.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Duration of use
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Experience
Number of responses to this question: not disclosed.
Effectiveness
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “273 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1TIPO-1 Phase IIB Trial (2008)Expression of concern published in 2013Abstract checked
AI-PREPARED SUMMARY
2008 24-week trial reported weight loss but carries a 2013 Lancet expression of concern; treat efficacy estimates cautiously.
Major evidence-quality caveat
The Lancet issued an expression of concern about the widely cited 2008 trial. Its headline weight-loss estimates should not be presented as uncontested evidence.
Pep-Pedia bibliography · Checked 2026-10-12
2Expression of concern: tesofensine bodyweight-loss trialPrimary source checked
AI-PREPARED SUMMARY
Lancet published an expression of concern concerning the 2008 trial; this is distinct from a retraction.
Major evidence-quality caveat
The Lancet issued an expression of concern about the widely cited 2008 trial. Its headline weight-loss estimates should not be presented as uncontested evidence.
Additional research · Checked 2026-10-12
3Pep-Pedia: Tesofensine — community referenceCommunity source checked
AI-PREPARED SUMMARY
Accessed October 12, 2026. Secondary descriptions and bibliography; community schedules are unvalidated reports, not recommendations.
4TIPO-4 Extension Trial (48 weeks)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: An open-label extension reported maintenance of about 13–14 kg weight loss; continuing participants can differ from the original trial population.
Reported population / model
140 participants
Reported study details
0.5-1.0mg daily · 48 weeks · 13-14kg total weight loss
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Viking Phase 3 Trial (2018)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports successful weight and metabolic endpoints in a 372-participant registration study; detailed estimates are not supplied.
Reported population / model
372 participants
Reported study details
0.25-0.5mg daily · 24 weeks · Significant weight loss
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6GABAergic Hypothalamic Mechanism Study (2024)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Animal work implicated hypothalamic GABA neurons in appetite effects; a 5-HTP interaction does not establish a safe human combination.
Reported population / model
Animal model
Reported study details
Various doses · Acute/chronic · Neuronal activity
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Appetite Suppression Mechanism StudyPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat appetite suppression was linked to indirect alpha-1 and D1 signaling during two weeks of exposure.
Reported population / model
Rat model
Reported study details
2mg/kg · 14 days · Alpha-1 and D1 receptor pathways
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Pep-Pedia: Tesofensine — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 9.2 days and a peak time of 8 hrs. Stated attribution: Phase 2/3 Clinical Trials. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
9Pep-Pedia: Tesofensine — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12